Regeneron Pharmaceuticals. has filed a patent for a method of treating MUC16-expressing cancer, such as recurrent ovarian cancer. The method involves administering a bispecific antibody that binds to MUC16 on tumor cells and CD3 on T cells. The antibody is administered at a dose of at least 1 mg and has specific amino acid sequences for the antigen-binding domains. GlobalData’s report on Regeneron Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Regeneron Pharmaceuticals, Transgenic murine models was a key innovation area identified from patents. Regeneron Pharmaceuticals's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Method of treating muc16-expressing cancer using bispecific antibody
A recently filed patent (Publication Number: US20230312718A1) describes a method for treating MUC16-expressing cancer in patients. The method involves administering a bispecific antibody to the patient, which consists of two antigen-binding domains. The first domain specifically binds to MUC16 on tumor cells, while the second domain specifically binds to human CD3 on T cells. The bispecific antibody is administered at a minimum dose of 1 mg.
The patent claims that the first antigen-binding domain of the bispecific antibody consists of a heavy chain variable region (HCVR) and a light chain variable region (LCVR). These regions contain specific amino acid sequences (SEQ ID NOs: 8, 9, 10, 11, 12, and 13). Similarly, the second antigen-binding domain also consists of a HCVR and a LCVR with specific amino acid sequences (SEQ ID NOs: 14, 15, 16, 11, 12, and 13).
The method is specifically applicable to MUC16-expressing cancers such as ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is particularly useful for cancers that are resistant to platinum-based chemotherapy or have been previously treated with platinum-based chemotherapy.
The bispecific antibody can be administered in various dosing regimens, including a split initial dose or a weekly dose ranging from 10 mg to 1000 mg. In some cases, the dose can be split into different fractions. Additionally, the method allows for the administration of a second therapeutic agent or regimen, such as an anti-PD-1 antibody.
The patent also describes specific amino acid sequences for the anti-PD-1 antibody or antigen-binding fragment, which can be administered in a dose of 300 to 400 mg once every three weeks.
The method aims to achieve stable disease, partial response, or complete response in patients following the administration of the bispecific antibody. The bispecific antibody is designed to achieve a serum concentration of at least 4 mg/L.
The administration of the bispecific antibody can be done intravenously or subcutaneously, while the anti-PD-1 antibody or antigen-binding fragment is typically administered intravenously.
Overall, this patent presents a method for treating MUC16-expressing cancers using a bispecific antibody, potentially providing a new therapeutic option for patients with these types of cancers.
To know more about GlobalData’s detailed insights on Regeneron Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
